{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:08:33Z","timestamp":1790424513244,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancerop\u00f4le Lyon Auvergne Rh\u00f4ne-Alpes","award":["PDC-N\u00b022"],"award-info":[{"award-number":["PDC-N\u00b022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4544-x","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T08:14:33Z","timestamp":1528445673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-1254","authenticated-orcid":false,"given":"Anne-Laure","family":"Giraudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Alexandre","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chicaco","family":"Iwao-Fukukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Badel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kryza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gilles-Afchain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Clapisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Desuzinges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarrut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Halty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyomasa","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Baconnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Berge-Montamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"issue":"8","key":"4544_CR1","doi-asserted-by":"publisher","first-page":"e20294","DOI":"10.1371\/journal.pone.0020294","volume":"6","author":"F Ducimeti\u00e8re","year":"2011","unstructured":"Ducimeti\u00e8re F, Lurkin A, Ranch\u00e8re-Vince D, Decouvelaere AV, P\u00e9oc'h M, Istier L, Chalabreysse P, Muller C, Alberti L, Bringuier PP, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294.","journal-title":"PLoS One"},{"issue":"5","key":"4544_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2012.46.0147","volume":"31","author":"P Lagarde","year":"2013","unstructured":"Lagarde P, Przybyl J, Brulard C, P\u00e9rot G, Pierron G, Delattre O, Sciot R, Wozniak A, Sch\u00f6ffski P, Terrier P, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31(5):608\u201315.","journal-title":"J Clin Oncol"},{"key":"4544_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2016.02.002","volume":"58","author":"M Vlenterie","year":"2016","unstructured":"Vlenterie M, Liti\u00e8re S, Rizzo E, Marr\u00e9aud S, Judson I, Gelderblom H, Le Cesne A, Wardelmann E, Messiou C, Gronchi A, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group; setting a new landmark for studies in this entity. Eur J Cancer. 2016;58:62\u201372.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4544_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"S Sleijfer","year":"2010","unstructured":"Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72\u201383.","journal-title":"Eur J Cancer"},{"issue":"4","key":"4544_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/CCO.0b013e328354c141","volume":"24","author":"K Do","year":"2012","unstructured":"Do K, Doroshow JH, Kummar S. Antiangiogenic approaches for the treatment of advanced synovial sarcomas. Curr Opin Oncol. 2012;24(4):425\u201330.","journal-title":"Curr Opin Oncol"},{"key":"4544_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/TCRM.S84792","volume":"12","author":"LD Cranmer","year":"2016","unstructured":"Cranmer LD, Loggers ET, Pollack SM. Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag. 2016;12:941\u201355.","journal-title":"Ther Clin Risk Manag"},{"key":"4544_CR7","doi-asserted-by":"publisher","unstructured":"Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016; \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30507-1\n                    \n                  .","DOI":"10.1016\/S1470-2045(16)30507-1"},{"issue":"20","key":"4544_CR8","first-page":"5859","volume":"62","author":"S Nagayama","year":"2002","unstructured":"Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002;62(20):5859\u201366.","journal-title":"Cancer Res"},{"issue":"41","key":"4544_CR9","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1038\/sj.onc.1208780","volume":"24","author":"S Nagayama","year":"2005","unstructured":"Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N, Imamura M, Toguchida J, Nakamura Y. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005;24(41):6201\u201312.","journal-title":"Oncogene"},{"issue":"2","key":"4544_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1349-7006.2007.00701.x","volume":"99","author":"C Fukukawa","year":"2008","unstructured":"Fukukawa C, Hanaoka H, Nagayama S, Tsunoda T, Toguchida J, Endo K, Nakamura Y, Katagiri T. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008;99(2):432\u201340.","journal-title":"Cancer Sci"},{"issue":"1","key":"4544_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4544_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","volume":"105","author":"D Rizzieri","year":"2016","unstructured":"Rizzieri D. Zevalin(\u00ae) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016;105:5\u201317.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"4544_CR13","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182\u201391.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4544_CR14","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754\u201362.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4544_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O'Dorisio MS, O'Dorisio TM, O'Dorisiol TM, Howe JR, Cremonesi M, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"74","key":"4544_CR16","first-page":"71","volume":"14","author":"MS Hofman","year":"2012","unstructured":"Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14(74):71\u201381.","journal-title":"Discov Med"},{"issue":"1","key":"4544_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","volume":"22","author":"U Haberkorn","year":"2016","unstructured":"Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate Cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22(1):9\u201315.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4544_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7150\/thno.3645","volume":"2","author":"RP Baum","year":"2012","unstructured":"Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy - the Bad Berka experience. Theranostics. 2012;2(5):437\u201347.","journal-title":"Theranostics"},{"issue":"7","key":"4544_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-labeled prostate-specific membrane antigen Radioligand therapy of metastatic castration-resistant prostate Cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006\u201313.","journal-title":"J Nucl Med"},{"issue":"Suppl 3","key":"4544_CR20","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","volume":"57","author":"HR Kulkarni","year":"2016","unstructured":"Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, Wester HJ, Baum RP. PSMA-based Radioligand therapy for metastatic castration-resistant prostate Cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57(Suppl 3):97S\u2013104S.","journal-title":"J Nucl Med"},{"issue":"13","key":"4544_CR21","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","volume":"22","author":"MI Milowsky","year":"2004","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522\u201331.","journal-title":"J Clin Oncol"},{"issue":"19 Pt 2","key":"4544_CR22","doi-asserted-by":"publisher","first-page":"7195s","DOI":"10.1158\/1078-0432.CCR-1004-0023","volume":"11","author":"S Vallabhajosula","year":"2005","unstructured":"Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11(19 Pt 2):7195s\u2013200s.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4544_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40658-016-0172-1","volume":"4","author":"D Sarrut","year":"2017","unstructured":"Sarrut D, Badel JN, Halty A, Garin G, Perol D, Cassier P, Blay JY, Kryza D, Giraudet AL. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma. EJNMMI Phys. 2017;4(1):6.","journal-title":"EJNMMI Phys"},{"issue":"21","key":"4544_CR24","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591\u2013601.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4544_CR25","first-page":"114","volume":"5","author":"H Ahmadzadehfar","year":"2015","unstructured":"Ahmadzadehfar H, Rahbar K, K\u00fcrpig S, B\u00f6gemann M, Claesener M, Eppard E, G\u00e4rtner F, Rogenhofer S, Sch\u00e4fers M, Essler M. Early side effects and first results of radioligand therapy with (177) Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-Centre study. EJNMMI Res. 2015;5(1):114.","journal-title":"EJNMMI Res"},{"issue":"11","key":"4544_CR26","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.18632\/oncotarget.7245","volume":"7","author":"H Ahmadzadehfar","year":"2016","unstructured":"Ahmadzadehfar H, Eppard E, K\u00fcrpig S, Fimmers R, Yordanova A, Schlenkhoff CD, G\u00e4rtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477\u201388.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4544-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T19:12:07Z","timestamp":1559934727000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4544"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4544-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"31 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This clinical trial protocol and amendments was approved by French competent Authority, ANSM on 12th October 2011 and by French Ethic committee (CPP Sud-Est IV, Lyon, France) on 13th September 2011 and conducted in accordance with International Conference on Harmonization for Good Clinical Practice, and local regulations (European Directive 2001\/20\/EC). All patients provided written informed consent. The study was registered on the  website (NCT01469975).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript does not contain data from any individual person and it is not applicable in this section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Chicaco Iwao-Fukukawa; Masaharu Mori, Takuya Tsunoda, Toyomasa Katagiri, Yusuke Nakamura were\/are employees of Oncotherapy Science (Japan).Simon Baconnier was also an employee of OTS France.The remaining authors declare no competing interest with the study data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"646"}}